185 related articles for article (PubMed ID: 28151911)
1. Risk factors of hepatic dysfunction in patients with Graves' hyperthyroidism and the efficacy of 131iodine treatment.
Wang R; Tan J; Zhang G; Zheng W; Li C
Medicine (Baltimore); 2017 Feb; 96(5):e6035. PubMed ID: 28151911
[TBL] [Abstract][Full Text] [Related]
2. Risk factors of hyperthyroidism with hepatic function injury: a 4-year retrospective study.
Li C; Tan J; Zhang G; Meng Z; Wang R; Li W; Zheng W
Horm Metab Res; 2015 Mar; 47(3):209-13. PubMed ID: 24867136
[TBL] [Abstract][Full Text] [Related]
3. Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease.
Noh JY; Hamada N; Inoue Y; Abe Y; Ito K; Ito K
Thyroid; 2000 Sep; 10(9):809-13. PubMed ID: 11041459
[TBL] [Abstract][Full Text] [Related]
4. TRAb elevations occurred even in the third trimester; a case of a mother of a child with neonatal thyroid dysfunction, who received radioactive iodine therapy for Graves' disease.
Suzuki N; Yoshihara A; Yoshimura Noh J; Kinoshita K; Ohnishi J; Saito M; Sugino K; Ito K
Endocr J; 2020 Oct; 67(10):1019-1022. PubMed ID: 32522908
[TBL] [Abstract][Full Text] [Related]
5. Persistent high TRAb values during pregnancy predict increased risk of neonatal hyperthyroidism following radioiodine therapy for refractory hyperthyroidism.
Hamada N; Momotani N; Ishikawa N; Yoshimura Noh J; Okamoto Y; Konishi T; Ito K; Ito K
Endocr J; 2011; 58(1):55-8. PubMed ID: 20962435
[TBL] [Abstract][Full Text] [Related]
6. fT3:fT4 ratio in Graves' disease - correlation with TRAb level, goiter size and age of onset.
Minasyan M; Dulęba A; Smalarz A; Stręk M; Bryniarski P; Przybylik-Mazurek E; Hubalewska-Dydejczyk A
Folia Med Cracov; 2020 Sep; 60(2):15-27. PubMed ID: 33252592
[TBL] [Abstract][Full Text] [Related]
7. [The relationship between serum thyroid autoantibodies, iodine intake, development and prognosis of Graves' disease].
Chen W; Man N; Li YS; Shan ZY; Teng WP
Zhonghua Nei Ke Za Zhi; 2006 Feb; 45(2):95-9. PubMed ID: 16624113
[TBL] [Abstract][Full Text] [Related]
8. Persistent Graves' hyperthyroidism despite rapid negative conversion of thyroid-stimulating hormone-binding inhibitory immunoglobulin assay results: a case report.
Ohara N; Kaneko M; Kitazawa M; Uemura Y; Minagawa S; Miyakoshi M; Kaneko K; Kamoi K
J Med Case Rep; 2017 Feb; 11(1):32. PubMed ID: 28162094
[TBL] [Abstract][Full Text] [Related]
9. Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves' patients and in 686 normal subjects.
Takasu N; Oshiro C; Akamine H; Komiya I; Nagata A; Sato Y; Yoshimura H; Ito K
J Endocrinol Invest; 1997 Sep; 20(8):452-61. PubMed ID: 9364248
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for neonatal thyroid dysfunction in pregnancies complicated by Graves' disease.
Uenaka M; Tanimura K; Tairaku S; Morioka I; Ebina Y; Yamada H
Eur J Obstet Gynecol Reprod Biol; 2014 Jun; 177():89-93. PubMed ID: 24726178
[TBL] [Abstract][Full Text] [Related]
11. Preoperative change of thyroid stimulating hormone receptor antibody level: possible marker for predicting recurrent hyperthyroidism in patients with Graves' disease after subtotal thyroidectomy.
Sugino K; Mimura T; Ozaki O; Iwasaki H; Wada N; Matsumoto A; Ito K
World J Surg; 1996 Sep; 20(7):801-6; discussion 806-7. PubMed ID: 8678954
[TBL] [Abstract][Full Text] [Related]
12. Exacerbation of erythropoietic protoporphyria by hyperthyroidism.
Minder EI; Haldemann AR; Schneider-Yin X
J Inherit Metab Dis; 2010 Dec; 33 Suppl 3():S465-9. PubMed ID: 21069463
[TBL] [Abstract][Full Text] [Related]
13. The development of transient hypothyroidism after iodine-131 treatment in hyperthyroid patients with Graves' disease: prevalence, mechanism and prognosis.
Aizawa Y; Yoshida K; Kaise N; Fukazawa H; Kiso Y; Sayama N; Hori H; Abe K
Clin Endocrinol (Oxf); 1997 Jan; 46(1):1-5. PubMed ID: 9059550
[TBL] [Abstract][Full Text] [Related]
14. Analysis of ¹³¹I therapy and correlation factors of Graves' disease patients: a 4-year retrospective study.
Zheng W; Jian T; Guizhi Z; Zhaowei M; Renfei W
Nucl Med Commun; 2012 Jan; 33(1):97-101. PubMed ID: 22008631
[TBL] [Abstract][Full Text] [Related]
15. Low response of the thyroid gland to endogenous thyrotropin increased by thyrotropin-releasing hormone in patients with euthyroid Graves' disease.
Kashiwai T; Tada H; Watanabe Y; Shimaoka Y; Yagoro A; Hidaka Y; Fujikado T; Amino N
Thyroid; 1998 Oct; 8(10):881-5. PubMed ID: 9827654
[TBL] [Abstract][Full Text] [Related]
16. Long-term carbimazole intake does not affect success rate of radioactive 131Iodine in treatment of Graves' hyperthyroidism.
El Refaei SM; Shawkat W
Nucl Med Commun; 2008 Jul; 29(7):642-8. PubMed ID: 18528187
[TBL] [Abstract][Full Text] [Related]
17. Radioiodine therapy in Graves' disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy.
Sabri O; Zimny M; Schreckenberger M; Reinartz P; Ostwald E; Buell U
Thyroid; 1999 Dec; 9(12):1181-8. PubMed ID: 10646656
[TBL] [Abstract][Full Text] [Related]
18. Age Moderates the Impact of TRAbs on Thyroid Hormones and Hepatic Function in Patients with Graves' Disease.
Guo K; Ling H; Zhou X; Ying C
Horm Metab Res; 2021 Jul; 53(7):453-460. PubMed ID: 34282596
[TBL] [Abstract][Full Text] [Related]
19. Sensitive thyroid-stimulating antibody assay with high concentrations of polyethylene glycol for the diagnosis of Graves' disease.
Takasu N; Kamijo K; Sato Y; Yoshimura H; Nagata A; Ochi Y
Clin Exp Pharmacol Physiol; 2004; 31(5-6):314-9. PubMed ID: 15191404
[TBL] [Abstract][Full Text] [Related]
20. Prediction of late (24-hour) radioactive iodine uptake using early (3-hour) uptake values in Japanese patients with Graves' disease.
Osaki Y; Sakurai K; Arihara Z; Hata M; Fukazawa H
Endocr J; 2012; 59(2):173-7. PubMed ID: 22095001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
